The Association Between Primary Aldosteronism and Cognitive Dysfunction
Eligible age
40+ yrs
Accepts
All genders
Locations
0 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The goal of this observational study is to learn about the prevalence, progression, and influencing factors of cognitive impairment in patients with primary aldosteronism (PA). The main questions it aims to answer are: 1. What is the prevalence of baseline cognitive impairment in PA patients and what factors are associated with it? 2. What is the incidence of cognitive progression in PA patients within 1 and 5 years of follow-up and what factors influence this progression? Participants who are already diagnosed with PA as part of their regular medical care will be invited to join this long-term study. They will complete regular cognitive tests, medical check-ups, and questionnaires for up to 5 years. Some participants will also have optional blood tests and brain scans to help researchers understand the causes behind any cognitive changes.
Sponsor: Xinjiang Medical University
You may qualify if…
- ✓ 1\. Aged ≥ 40 years.
- ✓ 2\. Biochemically confirmed diagnosis of Primary Aldosteronism (PA) according to contemporary guidelines (e.g., confirmed positive case detection test and confirmatory test).
- ✓ 3\. Ability to understand and cooperate with comprehensive neuropsychological assessment.
- ✓ 4\. Voluntary participation and provision of written informed consent.
You may not qualify if…
- ✕ 1\. Significant visual, hearing, or motor impairment that prevents completion of cognitive testing.
- ✕ 2\. History of major neurological disorders (e.g., stroke, Parkinson's disease, intracranial tumor, severe traumatic brain injury).
- ✕ 3\. History of major psychiatric illness, intellectual disability, or current use of antipsychotic medications.
- ✕ 4\. Diagnosis of secondary hypertension other than PA.
- ✕ 5\. Unwillingness to participate by the patient or their legal representative.
Source: ClinicalTrials.gov · NCT07304674 · last updated 2026-01-05